Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of an underwritten public offering of 4,125,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of approximately $144.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on August 3, 2020, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 618,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Latham & Watkins LLP represents Zentalis Pharmaceuticals, Inc. in the upsized offering with a capital markets team led by San Diego partner Cheston Larson and New York partner Nathan Ajiashvili, with New York associates Salvatore Vanchieri, Matthew DeSilva, and Darby Dietrich.
Earlier this year, Latham represented Zentalis on its IPO, which was the first IPO to be executed using an all-virtual road show.